Table 2.
Sections and topics.
| Sections | Topics | Questions |
|---|---|---|
| 1 | Management of high‐risk and locally advanced prostate cancer | 1–20 |
| 2 | Oligometastatic prostate cancer | 21–30 |
| 3 | Management of CNPC | 31–49 |
| 4 | Management of CRPC | 50–87 |
| 5 | Use of osteoclast‐targeted therapy for SRE/SSE prevention for mCRPC (not for osteoporosis/bone loss) | 88–92 |
| 6 | Global access to prostate cancer drugs and treatment in countries with limited resources | 93–101 |
CNPC, castration‐naïve prostate cancer; CRPC, castration‐resistant prostate cancer; mCRPC, metastatic CRPC; SRE, skeletal‐ related event; SSE, symptomatic skeletal event.